Matches in SemOpenAlex for { <https://semopenalex.org/work/W2890153986> ?p ?o ?g. }
- W2890153986 endingPage "136" @default.
- W2890153986 startingPage "127" @default.
- W2890153986 abstract "Background We investigated the efficacy and safety of fulvestrant plus goserelin (F + G) versus anastrozole plus goserelin (A + G) in comparison with goserelin (G) alone in premenopausal women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), tamoxifen-pretreated metastatic breast cancer (MBC). Patients and methods In this multicentre, open-label, randomised phase II study, premenopausal women aged ≥18 years with HR+, HER2–, tamoxifen-pretreated MBC were randomly assigned (1:1:1) to F + G, A + G or G alone. The primary end-point was time to progression (TTP). Secondary end-points included overall survival, overall response rate, clinical benefit rate and toxicity. Results Of 138 eligible patients, 44 were randomly assigned to receive F + G, 47 to A + G and 47 to G alone. The median follow-up duration was 32.2 months (interquartile range: 23.69–40.86) and the median age was 43.0 years (range 23.0–55.0). The median TTP was 16.3 months (95% confidence interval [CI] 7.5–25.1) for F + G, 14.5 months (95% CI 11.0–18.0) for A + G and 13.5 months (95% CI 10.3–16.8) for G alone. Compared with G alone, the hazard ratios were 0.608 for F + G (95% CI, 0.370–0.998; p = 0.049) and 0.982 for A + G (95% CI, 0.624–1.546; p = 0.937). In terms of visceral metastasis, a stratification factor, there were no TTP differences according to treatment arm. Grade III or IV toxicities were rarely observed. Of the common adverse events, grade I arthralgia and joint stiffness were more frequently observed in the F + G than in the A + G or G-alone groups (p < 0.05, respectively). Conclusions F + G provides a promising new option for the treatment of premenopausal women with HR+, HER2-, tamoxifen-pretreated MBC. Trial registration ClinicalTrials.gov number NCT01266213 and Korean Cancer Study Group (KCSG) Breast cancer protocol number BR10-04." @default.
- W2890153986 created "2018-09-27" @default.
- W2890153986 creator A5007089296 @default.
- W2890153986 creator A5007992707 @default.
- W2890153986 creator A5012153148 @default.
- W2890153986 creator A5017506744 @default.
- W2890153986 creator A5026459010 @default.
- W2890153986 creator A5038366277 @default.
- W2890153986 creator A5038481896 @default.
- W2890153986 creator A5039319474 @default.
- W2890153986 creator A5049274095 @default.
- W2890153986 creator A5049348377 @default.
- W2890153986 creator A5051676656 @default.
- W2890153986 creator A5063587278 @default.
- W2890153986 creator A5069050806 @default.
- W2890153986 creator A5071276908 @default.
- W2890153986 creator A5072696954 @default.
- W2890153986 creator A5082025437 @default.
- W2890153986 creator A5084384049 @default.
- W2890153986 creator A5089465499 @default.
- W2890153986 date "2018-11-01" @default.
- W2890153986 modified "2023-09-26" @default.
- W2890153986 title "Fulvestrant plus goserelin versus anastrozole plus goserelin versus goserelin alone for hormone receptor-positive, HER2-negative tamoxifen-pretreated premenopausal women with recurrent or metastatic breast cancer (KCSG BR10-04): a multicentre, open-label, three-arm, randomised phase II trial (FLAG study)" @default.
- W2890153986 cites W1829247853 @default.
- W2890153986 cites W1893678663 @default.
- W2890153986 cites W1932574503 @default.
- W2890153986 cites W1968993577 @default.
- W2890153986 cites W1994783207 @default.
- W2890153986 cites W2032144589 @default.
- W2890153986 cites W2076951285 @default.
- W2890153986 cites W2107292392 @default.
- W2890153986 cites W2109997465 @default.
- W2890153986 cites W2114107283 @default.
- W2890153986 cites W2116144791 @default.
- W2890153986 cites W2171244965 @default.
- W2890153986 cites W2171458023 @default.
- W2890153986 cites W2290950904 @default.
- W2890153986 cites W2404884142 @default.
- W2890153986 cites W2505695170 @default.
- W2890153986 cites W2558360748 @default.
- W2890153986 cites W2560635244 @default.
- W2890153986 cites W2806866264 @default.
- W2890153986 cites W3141568964 @default.
- W2890153986 doi "https://doi.org/10.1016/j.ejca.2018.08.004" @default.
- W2890153986 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30223226" @default.
- W2890153986 hasPublicationYear "2018" @default.
- W2890153986 type Work @default.
- W2890153986 sameAs 2890153986 @default.
- W2890153986 citedByCount "9" @default.
- W2890153986 countsByYear W28901539862019 @default.
- W2890153986 countsByYear W28901539862020 @default.
- W2890153986 countsByYear W28901539862021 @default.
- W2890153986 countsByYear W28901539862022 @default.
- W2890153986 crossrefType "journal-article" @default.
- W2890153986 hasAuthorship W2890153986A5007089296 @default.
- W2890153986 hasAuthorship W2890153986A5007992707 @default.
- W2890153986 hasAuthorship W2890153986A5012153148 @default.
- W2890153986 hasAuthorship W2890153986A5017506744 @default.
- W2890153986 hasAuthorship W2890153986A5026459010 @default.
- W2890153986 hasAuthorship W2890153986A5038366277 @default.
- W2890153986 hasAuthorship W2890153986A5038481896 @default.
- W2890153986 hasAuthorship W2890153986A5039319474 @default.
- W2890153986 hasAuthorship W2890153986A5049274095 @default.
- W2890153986 hasAuthorship W2890153986A5049348377 @default.
- W2890153986 hasAuthorship W2890153986A5051676656 @default.
- W2890153986 hasAuthorship W2890153986A5063587278 @default.
- W2890153986 hasAuthorship W2890153986A5069050806 @default.
- W2890153986 hasAuthorship W2890153986A5071276908 @default.
- W2890153986 hasAuthorship W2890153986A5072696954 @default.
- W2890153986 hasAuthorship W2890153986A5082025437 @default.
- W2890153986 hasAuthorship W2890153986A5084384049 @default.
- W2890153986 hasAuthorship W2890153986A5089465499 @default.
- W2890153986 hasConcept C121608353 @default.
- W2890153986 hasConcept C126322002 @default.
- W2890153986 hasConcept C126894567 @default.
- W2890153986 hasConcept C143998085 @default.
- W2890153986 hasConcept C207103383 @default.
- W2890153986 hasConcept C2775930923 @default.
- W2890153986 hasConcept C2776215463 @default.
- W2890153986 hasConcept C2777176818 @default.
- W2890153986 hasConcept C2778043895 @default.
- W2890153986 hasConcept C29456083 @default.
- W2890153986 hasConcept C44249647 @default.
- W2890153986 hasConcept C530470458 @default.
- W2890153986 hasConcept C71924100 @default.
- W2890153986 hasConcept C90924648 @default.
- W2890153986 hasConceptScore W2890153986C121608353 @default.
- W2890153986 hasConceptScore W2890153986C126322002 @default.
- W2890153986 hasConceptScore W2890153986C126894567 @default.
- W2890153986 hasConceptScore W2890153986C143998085 @default.
- W2890153986 hasConceptScore W2890153986C207103383 @default.
- W2890153986 hasConceptScore W2890153986C2775930923 @default.
- W2890153986 hasConceptScore W2890153986C2776215463 @default.
- W2890153986 hasConceptScore W2890153986C2777176818 @default.
- W2890153986 hasConceptScore W2890153986C2778043895 @default.
- W2890153986 hasConceptScore W2890153986C29456083 @default.
- W2890153986 hasConceptScore W2890153986C44249647 @default.
- W2890153986 hasConceptScore W2890153986C530470458 @default.